---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-003126"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2026-05-14T20:18:53+00:00"
generated_at: "2026-05-14T20:46:38.860348+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test

## Summary
- Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.
- Net cash used in operations was $5.3M; raised $5.4M from ATM equity and $1.9M from convertible note.
- Received $1M in non-dilutive Walloon Region funding; ~$0.9M more expected over 12 months.
- Feline lymphoma assay manuscript submitted for peer review; expected to unlock $5M milestone payment.
- Discussions ongoing with >12 diagnostic companies for licensing; Nu.Q Lung Cancer reimbursement in France progressing.

## SEC filing metadata
- accession: 0001477932-26-003126
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2026-05-14T20:18:53+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793226003126/0001477932-26-003126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793226003126/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-003126
- JSON: https://secwatch.observer/filing/0001477932-26-003126.json
- Plain text: https://secwatch.observer/filing/0001477932-26-003126.txt

## Key facts
- Earnings Releases
  VOLITIONRX LTD reported the first quarter 2026 results: revenue $1.0 million.
  - Period: the first quarter 2026
  - Revenue: $1.0 million
  - Result: reported results
  source text: pillars; our laser focus is on executing licensing agreements and we will update you as they progress.” 1 Financial Highlights · Revenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025. · Operating loss was down 3% for the quarter versus the comparable quarter in 2025. · Net cash used in operating activities
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793226003126/0001477932-26-003126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.